Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.
Nevertheless, researchers are hoping to learn more from the study of the caspase inhibitor among people with non-alcoholic steatohepatitis.
Conatus Pharmaceuticals’ study of emricasan for non-alcoholic steatohepatitis found the drug had no significant impact.
A quick overview of our reporting on the 53rd International Liver Congress in Vienna
At the 24-week mark of a 48-week trial, the treatment showed a trend toward a lack of efficacy.
The NAFLD/NASH medications’ page includes specific information about each of the experimental dru...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.